JPMorgan Chase & Co. Lowers Stock Position in Inogen, Inc. (NASDAQ:INGN)

JPMorgan Chase & Co. trimmed its holdings in Inogen, Inc. (NASDAQ:INGN) by 30.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 627,030 shares of the medical technology company’s stock after selling 269,076 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.63% of Inogen worth $5,750,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of INGN. AlphaQuest LLC acquired a new position in Inogen in the fourth quarter valued at $43,000. Ieq Capital LLC purchased a new position in shares of Inogen during the fourth quarter worth about $94,000. Intech Investment Management LLC purchased a new position in shares of Inogen during the fourth quarter worth about $94,000. Summit Global Investments acquired a new position in Inogen in the 4th quarter valued at about $107,000. Finally, Virtu Financial LLC purchased a new stake in Inogen during the 3rd quarter valued at approximately $111,000. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Stock Down 0.9 %

Shares of NASDAQ:INGN opened at $6.82 on Friday. Inogen, Inc. has a 52 week low of $6.40 and a 52 week high of $13.33. The company has a 50-day moving average price of $8.02 and a 200 day moving average price of $9.16. The company has a market cap of $183.37 million, a P/E ratio of -3.03 and a beta of 1.48.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research note on Wednesday, April 9th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.